Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
Key Highlights
- ➤Evaxion (EVAX) wins 2026 International Prix Galien Award for best digital health solution
- ➤AI-Immunology™ earns first International Prix Galien Award for a Danish company
- ➤EVX-01 three-year Phase 2 data showed durable outcomes and immune activation in advanced melanoma
- ➤Evaxion says AI-Immunology™ supports target discovery, drug design and immunotherapy development
Expert Statements
Helen Tayton-Martin, CEO of Evaxion
“The International Prix Galien Award is a tremendous recognition of our science and technology, which we are honored and delighted to receive. Having been refined, trained and enhanced for almost two decades, AI-Immunology™ is a leading and clinically validated platform for novel immune drug target discovery, especially in cancer vaccines. We are delighted by this distinction, which strongly endorses our approach in leveraging AI to develop new treatments”
* This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™ COPENHAGEN, Denmark, October 30, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, is proud to have been awarded the 2026 International Prix Galien Award for AI-Immunology™ as best digital health solution. It is the first time the prestigious international award has been won by a Danish company.
Evaxion CEO Helen Tayton-Martin and founder and Chief AI Officer Andreas Holm Mattsson received the award last night at the American Museum of Natural History in New York City. It represents yet another important external recognition of AI-Immunology™, which harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.
Get started
Create a free account to read the full story.